A randomized, double-blind, placebo-controlled, single-dose Phase I study to evaluate the pharmacokinetics, safety, and tolerability of FEP-ZID in healthy Chinese subjects
Latest Information Update: 07 Oct 2025
At a glance
- Drugs Cefepime/zidebactam (Primary)
- Indications Pyelonephritis; Urinary tract infections
- Focus Pharmacokinetics
Most Recent Events
- 07 Oct 2025 New trial record